Correction: Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy.
Sinha S, Dwivedi N, Tao S, Jamadar A, Kakade VR, O' Neil M, Weiss RH, Enders J, Calvet JP, Thomas SM, Rao R.
Sinha S, et al. Among authors: thomas sm.
Oncogene. 2025 Jan 27. doi: 10.1038/s41388-025-03279-2. Online ahead of print.
Oncogene. 2025.
PMID: 39870786
No abstract available.